Asset Details
Do you wish to reserve the book?
Antemortem CSF A β 42/A β 40 ratio predicts Alzheimer's disease pathology better than A β 42 in rapidly progressive dementias
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Antemortem CSF A β 42/A β 40 ratio predicts Alzheimer's disease pathology better than A β 42 in rapidly progressive dementias
Do you wish to request the book?
Antemortem CSF A β 42/A β 40 ratio predicts Alzheimer's disease pathology better than A β 42 in rapidly progressive dementias
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Antemortem CSF A β 42/A β 40 ratio predicts Alzheimer's disease pathology better than A β 42 in rapidly progressive dementias
2019
Overview
Despite the critical importance of pathologically confirmed samples for biomarker validation, only a few studies have correlated CSF A
42 values in vivo with postmortem Alzheimer's disease (AD) pathology, while none evaluated the CSF A
42/A
40 ratio. We compared CSF A
42 and A
42/A
40 ratio as biomarkers predicting AD neuropathological changes in patients with a short interval between lumbar puncture and death.
We measured CSF A
40 and A
42 and assessed AD pathology in 211 subjects with rapidly progressive dementia (RPD) and a definite postmortem diagnosis of Creutzfeldt-Jakob disease (
= 159), AD (
= 12), dementia with Lewy bodies (DLB,
= 4), AD/DLB mixed pathologies (
= 5), and various other pathologies (
= 31).
The score reflecting the severity of A
pathology showed a better correlation with ln(A
42/A
40) (
= 0.506,
= -0.713,
< 0.001) than with ln(A
42) (
= 0.206,
= -0.458,
< 0.001), which was confirmed after adjusting for covariates. A
42/A
40 ratio showed significantly higher accuracy than A
42 in the distinction between cases with or without AD pathology (AUC 0.818 ± 0.028 vs. 0.643 ± 0.039), especially in patients with A
42 levels ≤495 pg/mL (AUC 0.888 ± 0.032 vs. 0.518 ± 0.064). Using a cut-off value of 0.810, the analysis of A
42/A
40 ratio yielded 87.0% sensitivity, 88.2% specificity in the distinction between cases with an intermediate-high level of AD pathology and those with low level or no AD pathology.
The present data support the use of CSF A
42/A
40 ratio as a biomarker of AD pathophysiology and noninvasive screener for A
pathology burden, and its introduction in the research diagnostic criteria for AD.
Publisher
John Wiley & Sons, Inc
Subject
/ Alzheimer Disease - cerebrospinal fluid
/ Alzheimer Disease - diagnosis
/ Alzheimer Disease - pathology
/ Amyloid beta-Peptides - cerebrospinal fluid
/ Biomarkers - cerebrospinal fluid
/ Cognitive Dysfunction - cerebrospinal fluid
/ Cognitive Dysfunction - diagnosis
/ Cognitive Dysfunction - pathology
/ Dementia
/ Dementia - cerebrospinal fluid
/ Female
/ Humans
/ Lewy Body Disease - diagnosis
/ Lewy Body Disease - pathology
/ Male
